Skip to main content
. 2024 Aug 20;15:1413233. doi: 10.3389/fimmu.2024.1413233

Figure 6.

Figure 6

Differences in CD8 subpopulations before and after treatment. Percentages of (A) CD8 naïve (CD3+CD8+CD27+CCR7+CD45RA+) and (B) total CD8 T cells in peripheral blood in patients before (n = 14) and 6 months after treatment (n = 24) with omalizumab.